Clinical Trial Update: Post Approval Study of the Eversense® Continuous Glucose Monitoring [NA]

View source ↗

Summary

Post-approval study of the Eversense CGM has completed and posted results, evaluating real-world performance and safety in diabetes patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus
• Type 1 Diabetes Mellitus
• Type 2 Diabetes Mellitus

Drugs mentioned

• Eversense CGM (continuous glucose monitor)

Snippet

Sponsor: Senseonics, Inc. | Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 1 | NA | Status: COMPLETED | Results posted: 2025-06-12